New Parkinson’s Therapy Shows Promise for Patients with GBA1 Mutations

Portuguese biopharmaceutical company BIAL has announced a major milestone in its clinical trial for a potential new treatment for Parkinson’s disease in patients with a specific genetic mutation. The first patient has completed the full course of the treatment, known as BIA 28-6156, as part of the Phase 2 ACTIVATE study. What Is BIA 28-6156? BIA 28-6156 is an experimental medication designed to treat Parkinson’s disease in patients with a mutation in the GBA1 gene. This mutation affects an enzyme called glucocerebrosidase (GCase), which plays a key role in recycling certain fats in the body. People with this mutation tend to develop Parkinson’s symptoms earlier, experience faster disease progression, and have more severe symptoms than others with the condition. BIA 28-6156 is a daily pill that works by boosting GCase activity, helping to restore the body's natural recycling process. If successful, it could be the first treatment to directly address the root cause of the disease in these patients, potentially slowing down or modifying its progression. Progress in the Clinical Trial The ACTIVATE Phase 2 trial is a rigorous study testing BIA 28-6156 in over 230 patients across Europe and North America. Participants were randomly assigned to receive either the medication or a placebo, with doses of 10mg or 60mg per day. Researchers are monitoring the drug’s effectiveness, safety, and how it interacts with the body. Results are expected by mid-2026. Professor Joaquim Ferreira, a neurologist involved in the trial, highlighted the significance of this milestone: “This step reflects real progress toward better treatment options for Parkinson’s, especially for patients with GBA1 mutations. There’s immense hope in the potential of this therapy.” Why This Matters Parkinson’s disease affects over 10 million people worldwide, and 5–15% of patients carry mutations in the GBA1 gene. These mutations not only increase the risk of Parkinson’s but also worsen its symptoms and progression. Current treatments mostly manage symptoms rather than addressing the underlying causes, leaving a critical need for innovative therapies. BIA 28-6156 could become a game-changer, offering a targeted approach that benefits not just patients with GBA1 mutations but potentially the broader Parkinson’s community. Looking Ahead The completion of treatment by the first patient in the trial is a crucial step in testing the effectiveness of BIA 28-6156. With more data expected in 2026, researchers are optimistic about the impact this drug could have on improving the lives of people with Parkinson’s. Meanwhile, BIAL remains focused on finding transformative solutions for neurodegenerative diseases.